Clinical outcomes of early-stage breast cancer in Morocco: A cohort of 400 women

Figure 1 Overall survival, disease-free survival and locoregional recurrence-free survival in women with early breast cancer in Morocco. A: Overall survival; B: Disease-free survival; C: Locoregional recurrence-free survival.

Figure 2 Overall survival in women with early breast cancer in Morocco according to prognostic factors (log-rank test). A: Overall survival (OS) according to age (> 40 years vs < 40 years); B: OS according to nodal status (negative vs positive); C: OS according to American Joint Committee on Cancer (AJCC) stage (stage I-II vs stage III); D: OS according to Scarff-Bloom-Richardson grade (grade 1 vs grade 2 vs grade 3).

Figure 3 Clinical outcomes in women with early breast cancer in Morocco according to prognostic factors (log-rank test). A: Overall survival according to hormone receptor (HR) status; B: Disease-free survival according to HR status.

Figure 4 Hazard regression plots. A: Multivariate analysis of overall survival; B: Multivariate analysis of disease-free survival. CMF: Cyclophosphamide, methotrexate, fluorouracil; HR: Hormone receptor; IDC: Invasive ductal carcinoma; ILC: Invasive lobular carcinoma; SBR: Scarff-Bloom-Richardson.

Figure 5 Disease-free survival in women with early breast cancer in Morocco according to prognostic factors (log-rank test). A: Disease-free survival (DFS) according to age (> 40 years vs < 40 years); B: DFS according to nodal status (negative vs positive); C: DFS according to American Joint Committee on Cancer (AJCC) stage (stage I-II vs stage III); D: DFS according to Scarff-Bloom-Richardson grade (grade 1 vs grade 2 vs grade 3).